Thursday, June 23, 2016 6:05:23 AM
Between this post and the related slide
(source) and this slide
(source) several PS receptors were added. We now have the PS receptors on
IMC: MDSC, Macrophages, T-Cell
TIM: Tim1, Tim3, Tim4
TAM: Axl, Mer, Tyro-3
Others: CD300a, RAGE, BAI-1, Stabilin
If Phosphatidylserine gets exposed it will WITHOUT DISCRIMINATION affect and bind ALL above PS receptors at the SAME TIME thereby implementing a global/upstream/systemic strategy to suppress the Immune System from intervening in the Natural Cell Death cycle (apoptosis).
One can immediately see that binding only TIM-1 as does Celldex or TIM-3 as does Novartis, or Axl as does Genentech doesn't implement a GLOBAL approach but just disables ONE specific receptor from binding with PS.
PPHM's Bavituximab and new BetaBodies however CAPS PS itself thereby disabling it from binding with all 12 PS receptors at ones and hence avoid not only suppression by the immune system but also stimulates the immune system to activate (which is a requirement).
Therefor acquiring the patents of PPHM, that cover this broad global approach achieve several things:
- no 12 different drugs needed in I-O combination
- no 12 dosings needed (because all these types of receptors do NOT occur in the same amounts)
- no mine-field of clinical trials to test all these combo's with PD-1, PD-L1, CTLA-4, etc.
- next generation not needing the presence of blood already available
- much higher binding instance because Bavituximab binds the exposed PS on non-mobile cells and reduced amounts in micro vesicles while all others target receptors on immune system cells that move and would have to meet THEIR PS receptor compatible molecule (out of 12) to bind.
- NO T-Cell PS receptor ONLY binding involved (wanted or as side effect (see TIM-3).
- immune system suppression BLOCKING and immune system stimulation at the SAME time
- Immune Response against relapse possible because of that and ONLY because of that.
Additionally other measures are possible. One can try to give transfusions to REMOVE floating PS from the blood stream WITHOUT ANY HARM DONE and so doing lower the amount of PS! One can not do that to the Immune-Cell holding the above mentioned PS Receptors because those cells are NEEDED.
So personally, while I agree that CEO King said that PPHM does not own the complete PS field, I think PPHM holds the patents to the ONLY strategy that can GUARANTEE that a PS molecule, when CAPPED, is disabled for ALL PS receptors at the same time and that wit ONE SINGLE drug to add to a combo.
Furthermore this works for Oncology, Inflamations/Infections, Viral, Surgery/Injury and actually in ALL CASES where a cell exposes PS while NOT due to the natural cell death cycle and where it mistakenly has the side-effect of suppressing the immune system.
PPHM holds all those patents.
Peregrine Pharmaceuticals the Microsoft of Biotechnology! All In My Opinion. I am not advising anything, nor accusing anyone.
Recent CDMO News
- Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference • GlobeNewswire Inc. • 09/12/2024 08:05:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 09/09/2024 08:43:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:19:30 PM
- Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024 • GlobeNewswire Inc. • 09/09/2024 08:05:31 PM
- U.S. Futures Rise Amid Inflation Report Anticipation; Oil Prices Climb on Hurricane Threat and Supply Concerns • IH Market News • 09/09/2024 10:09:14 AM
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:30:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/28/2024 08:34:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/28/2024 08:32:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • SMX • Oct 3, 2024 7:00 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM